@article{ATM29150,
author = {Daniel Hyuck-Min Kwon and Terence Friedlander},
title = {A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 8},
year = {2019},
keywords = {},
abstract = {Metastatic prostate cancer, which presents as either de novo (4–5% of cases) or as a recurrence following definitive therapy for localized disease, has historically been treated with androgen deprivation therapy (ADT) alone. Although 90% of men initially respond to ADT, almost all eventually become castration-resistant and develop progression of their disease.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/29150}
}